Navigation Links
Harvest Technologies Corporation Granted CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia
Date:11/19/2012

PLYMOUTH, Mass., Nov. 19, 2012 /PRNewswire/ -- Harvest Technologies, a leader in advancing cellular therapies, is pleased to announce CE Marking for an expanded clinical indication for its SmartPReP®2 Bone Marrow Aspiration Concentration System (BMAC®2) product.

The British Standards Institution (BSI), a notified body under the Medical Device Directive, has awarded a certificate indicating that the Harvest SmartPReP2 Bone Marrow Aspiration Concentrate System (BMAC2) is intended to be used at point-of-care for the safe and rapid preparation of autologous nucleated cell concentrate from Bone Marrow Aspiration (BMA) for administration into ischemic tissues of the affected limb due to No-Option Critical Limb Ischemia.

This is the first time an autologous point-of-care cellular therapy company has presented sufficient clinical evidence for a notified body to grant approval to promote a specific product for this clinical use.  

This certification comes after BSI's extensive review of clinical data from nearly 50 clinical trials and investigations, including data using Harvest Technologies BMAC2 System.  Previous studies have shown that critical limb ischemia (CLI) patients that have tissue loss (gangrenous or ulcer wounds) are at severe risk for amputation.  Harvest studies have shown that the use of the BMAC2 system significantly reduces that risk and is a viable option for limb salvage. The Harvest studies have also been able to show improvement in rest pain for patients with severe rest pain.  

"We are pleased about the expansion of our claims.  This indication provides a significant treatment option that can improve the quality of life for approximately 800,000 European patients annually that progress to end stage critical limb ischemia," said Gary Tureski, President and CEO, Harvest Technologies Corporation. "The clinical evidence from our European studies is so compelling that we committed to and are currently enrolling patients in a US FDA pivotal trial."  

Harvest Technologies is the leading Cellular Therapy global manufacturer that develops point-of-care products to process and concentrate multiple biologics.  These include high-density platelet rich plasma (APC), bone marrow aspirate concentrate (BMAC®) and adipose tissue.  The company is headquartered in Plymouth, Massachusetts.  It is one of several subsidiaries of Terumo Corporation of Japan that is focused in cellular therapies and biologics.  For more information, visit www.harvesttech.com.

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.

Harvest Technologies Corporation
Plymouth, MA  02360
(877) 842-7837

Harvest, SmartPReP and BMAC are registered trademarks of Harvest Technologies Corporation.  Terumo® is a registered trademark of Terumo Corporation.


'/>"/>
SOURCE Harvest Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
2. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
3. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
4. Acuo Technologies Selected in Department of Defense Award to Deliver Vendor Neutral Archive for U.S. Army and U.S. Navy Medical Commands
5. Medisafe 1 Technologies Signs the $7MM Perpetual License Agreement
6. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
7. Filtrona Porous Technologies präsentiert neue medizinische Schäume und einzigartige Faserprodukte für saubere Arbeitsumgebungen auf MEDICA / COMPAMED-Messe
8. Beyond Lucid Technologies Receives Funding From Dalmore Investments
9. Filtrona Porous Technologies Introduces New Medical-Grade Foams And Unique Fiber Products For Clean Environments At MEDICA / COMPAMED Trade Fair
10. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
11. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
(Date:6/30/2017)... June 30, 2017  AVACEN Medical (AVACEN) announced the publication of ... describes the use of its AVACEN Treatment Method to ... fibromyalgia. ... AVACEN Medical ... chronic widespread pain. It affects approximately 200 to 400 million people worldwide ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... Bernard R. ... Past President of the American Orthopaedic Society of Sports Medicine (AOSSM) , received ... during the AOSSM Annual Meeting in Toronto, Canada. This prestigious award is given annually ...
(Date:7/21/2017)... , ... July 21, 2017 , ... “Kids aren't born ... to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company ... which launches on Kickstarter on Monday, July 21st. , The kit uses colorful, ...
(Date:7/21/2017)... ... July 21, 2017 , ... How ... are on the rise, say researchers presenting their work at the American ... , “The combination of evaluating the patterns of change in concussion symptom presentation, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Coats Rose, ... pleased to announce their expansion to the Midwest with the establishment of the ... and Ronald Bell, and of counsels, John Peck and Robert Bruns, will establish ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar ... non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it has ... to complete regulatory submissions and fund final engineering and initial production of the ...
Breaking Medicine News(10 mins):